Similar articles

• Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.

  Aggio FB, Melo GB, Höfling-Lima AL, Eid Farah M. Aggio FB, et al. Acta Ophthalmol Scand. 2006 Dec;84(6):831-3. doi: 10.1111/j.1600-0420.2006.00764.x. Acta Ophthalmol Scand. 2006. PMID: 17083553 No abstract available.
• Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.

  Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Bashshur ZF, et al. Arch Ophthalmol. 2007 Oct;125(10):1357-61. doi: 10.1001/archopht.125.10.1357. Arch Ophthalmol. 2007. PMID: 17923543 Clinical Trial.
• Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.

  Bakri SJ, Couch SM, McCannel CA, Edwards AO. Bakri SJ, et al. Retina. 2009 May;29(5):573-8. doi: 10.1097/IAE.0b013e3181a46a8a. Retina. 2009. PMID: 19430278
• [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

  Meyer CH, Helb HM, Eter N. Meyer CH, et al. Ophthalmologe. 2008 Feb;105(2):125-38, 140-2. doi: 10.1007/s00347-008-1702-6. Ophthalmologe. 2008. PMID: 18256841 Review. German.
• Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

  Kourlas H, Abrams P. Kourlas H, et al. Clin Ther. 2007 Sep;29(9):1850-61. doi: 10.1016/j.clinthera.2007.09.008. Clin Ther. 2007. PMID: 18035187 Review.